Hemab Therapeutics stock price target raised to $52 by H.C. Wainwright on trial data
Hemab Therapeutics stock price target raised to $52 by H.C. Wainwright on trial data
Hemab Therapeutics stock price target raised to $52 by H.C. Wainwright on trial data
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.